[1] P. Korge, M. L. Silber and P. D. Gollnick, “Effect of Creatine Phosphate on the Contractile Activity in Acutely Failing Rat Heart,” Cardiologia, Vol. 43, No. 12, 1998, pp. 1345-1354.
[2] V. A. Saks, I. V. Dzhaliashvili, E. A. Konorev, E. Strumia, “Molecular and Cellular Aspects of the Cardioprotective Mechanism of Phosphocreatine,” Biokhimiia, Vol. 57, No. 12, 1992, pp. 1763-1784.
[3] V. G. Sharov, N. I. Afonskaya, M. Y. Ruda, N. M. Cherpachenko, EYa Pozin, R. A. Markosyan, II Shepeleva, M. B. Samarenko and V. A. Saks, “Protection of Ischemic Myocardium by Exogenous Phosphocreatine (Neoton): Pharmacokinetics of Phosphocreatine, Reduction of Infarct Size, Stabilization of Sarcolemma of Ischemic Cardiomyocytes, and Antithrombotic Action,” Biochemical Medicine and Metabolic Biology, Vol. 35, No. 1, 1986, pp. 101-114. http://dx.doi.org/10.1016/0885-4505(86)90064-2
[4] E. Strumia, F. Pelliccia and G. D’Ambrosio, “Creatine Phosphate: Pharmacological and Clinical Perspectives,” Advances in Therapy, Vol. 29, No. 2, 2012, pp. 99-123. http://dx.doi.org/10.1007/s12325-011-0091-4
[5] W. Martindale, “Martindale: The Extra Pharmacopocia,” 31st Edition, The Royal Pharmaceutical Society, 1996.
[6] P. Korge, M. L. Silber and P. D. Gollnick, “Effect of Creatine Phosphate on the Contractile Activity in Acutely Failing Rat Heart,” Cardiologia, Vol. 43, No. 12, 1998, pp. 1345-1354.
[7] P. Mastroroberto, L. Di Tommaso and M. Chello, “Creatine Phosphate Protection of the Ischemic Myocardium during Cardiac Surgery,” Current Therapeutic Research, Vol. 51, No. 1, 1992, pp. 37-45.
[8] G. Prabhakar, L. Vona-Davis, D. Murray, P. Lakhani and G. Murray, “Phosphocreatine Restores High-Energy Phosphates in Ischemic Myocardium: Implication for Off-Pump Cardiacre Vascularization,” Journal of the American College of Surgeons, Vol. 197, No. 5, 2003, pp. 786-791. http://dx.doi.org/10.1016/j.jamcollsurg.2003.05.001
[9] MYa Ruda, M. B. Samarenko, N. I. Afonskaya and V. A. Saks, “Redtion of Ventricular Arrhythmias by Phosphocreatine (Neoton) in Patients with Acute Myocardial Infarction,” American Heart Journal, Vol. 116, No. 2, 1988, pp. 393-397. http://dx.doi.org/10.1016/0002-8703(88)90611-4
[10] M. L. Semenovsky, V. I. Shumakov, V. G. Sharov, G. M. Mogilevsky, A. V. Asmolovsky, L. A. Makhotina and V. A. Saks, “Protection of Ischemic Myocardium by Exogenous Phosphocreatine. II. Clinical, Ultrastructural, and Biochemicalevaluations,” Journal of Thoracic and Cardiovascular Surgery, Vol. 94, No. 5, 1987, pp. 762-769.
[11] E. Lorenzi, G. Piacenza, E. Strumia and R. Borgoglio, “Pharmacokinetics of Phosphocreatine Following Intravenous Administration in Humans and Effect on Blood Levels of ATP,” Cardiologia, Vol. 32, No. 9, 1987, pp. 1031-1034.
[12] M. Balestrino, M. Lensman, M. Parodi, L. Perasso, R. Rebaudo, R. Melani, S. Polenov and A. Cupello, “Role of Creatine and Phosphocreatine in Neuronal Protection from Anoxic and Ischemic Damage,” Amino Acids, Vol. 23, No. 1-3, 2002, pp. 221-229. http://dx.doi.org/10.1007/s00726-001-0133-3
[13] G. J. Brewer and T. W. Wallimann, “Protective Effect of the Energy Precursor Creatine against Toxicity of Glutamate and Beta-Amyloid in Rat Hippocampal Neurons,” Journal of Neurochemistry, Vol. 74, No. 5, 2000, pp. 1968-1978. http://dx.doi.org/10.1046/j.1471-4159.2000.0741968.x
[14] M. A. Tarnopolsky and M. F. Beal, “Potential for Creatine and Other Therapies Targeting Cellular Energy Dysfunction in Neurological Disorders,” Annals of Neurology, Vol. 49, No. 5, 2001, pp. 561-574. http://dx.doi.org/10.1002/ana.1028.abs
[15] T. Teerlink, M. Hennekes, J. Bussemaker and J. Groeneveld, “Simultanous Determination of Creatine Compoumds and Adenine Nucleotides in Myocardial Tissue by High-Performance Liquid Chromatography,” Analytical Biochemistry, Vol. 214, No. 1, 1993, pp. 278-283. http://dx.doi.org/10.1006/abio.1993.1488
[16] A. Ally and G. Park, “Rapid Determination of Creatine, Phosphocreatine, Purine Bases and Nucleotides (ATP, ADP, AMP, GTP, GDP) Inheart Biopsies by Gradiention-Pair Reversed-Phase Liquid,” Journal of Chromatography, Vol. 575, No. 1, 1992, pp. 19-27.
[17] A. M. Persky, M. Müller, H. Derendorf, M. Grant, G. A. Brazeau and G. Hochhaus, “Singleand Multiple-Dose Pharmacokinetics of Oral Creatine,” Journal of Clinical Pharmacology, Vol. 43, No. 1, 2003, pp. 29-37. http://dx.doi.org/10.1177/0091270002239703
[18] M. Levine, C. Conry-Cantilena, Y. Wang, R. W. Welch, P. W. Washko, K. R. Dhariwal, J. B. Park, A. Lazarev, J. F. Graumlich, J. King and L. R. Cantilena, “Vitamin C Pharmacokinetics in Healthy Volunteers: Evidence for a Recommended Dietary Allowance,” Proceedings of the National Academy of Sciences USA, Vol. 93, No. 8, 1996, pp. 3704-3709. http://dx.doi.org/10.1073/pnas.93.8.3704